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Abstract
Central nervous system (CNS) invasion during acute-stage HIV-infection has been demonstrated in a small number of
individuals, but there is no evidence of neurological impairment at this stage and virus infection in brain appears to be
controlled until late-stage disease. Using our reproducible SIV macaque model to examine the earliest stages of infection in
the CNS, we identified immune responses that differentially regulate inflammation and virus replication in the brain
compared to the peripheral blood and lymphoid tissues. SIV replication in brain macrophages and in brain of SIV-infected
macaques was detected at 4 days post-inoculation (p.i.). This was accompanied by upregulation of innate immune
responses, including IFNb, IFNb-induced gene MxA mRNA, and TNFa. Additionally, IL-10, the chemokine CCL2, and
activation markers in macrophages, endothelial cells, and astrocytes were all increased in the brain at four days p.i. We
observed synchronous control of virus replication, cytokine mRNA levels and inflammatory markers (MHC Class II, CD68 and
GFAP) by 14 days p.i.; however, control failure was followed by development of CNS lesions in the brain. SIV infection was
accompanied by induction of the dominant-negative isoform of C/EBPb, which regulates SIV, CCL2, and IL6 transcription, as
well as inflammatory responses in macrophages and astrocytes. This synchronous response in the CNS is in part due to the
effect of the C/EBPb on virus replication and cytokine expression in macrophage-lineage cells in contrast to CD4+
lymphocytes in peripheral blood and lymphoid tissues. Thus, we have identified a crucial period in the brain when virus
replication and inflammation are controlled. As in HIV-infected individuals, though, this control is not sustained in the brain.
Our results suggest that intervention with antiretroviral drugs or anti-inflammatory therapeutics with CNS penetration
would sustain early control. These studies further suggest that interventions should target HIV-infected individuals with
increased CCL2 levels or HIV RNA in the CNS.
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Introduction
HIV infection of the brain is thought to occur during acute
infection based on a limited number of case reports and studies
[1–3]. Because the earliest stage of infection cannot be studied in
humans, it is not clear whether acute infection in the central
nervous system (CNS) elicits inflammatory responses similar to
those that are observed during late-stage infection in the brain. It
has been postulated that HIV infection is cleared from the brain
after acute infection, and that CNS deficits occur because of re-
entry of virus into the CNS during late-stage disease—when there
is high viral load in peripheral blood and immune impairment
[4,5]. This is particularly relevant in the current HAART-era,
when patients frequently maintain suppression of virus replication
in the peripheral blood. Despite this control of patient virus
replication, HIV-associated neurocognitive disorders are prevalent
and increasing [6–8]. Thus, it is essential to understand the innate
mechanisms in the brain that may naturally suppress both virus
replication and the accompanying inflammatory responses that are
linked to eventual loss of neuronal function and neuronal apoptosis
in the CNS.
The regulation of virus replication in the brain and the
peripheral blood may be different because productively infected
cells in brain are of macrophage-lineage, in contrast to CD4+
lymphocyte in the peripheral blood and immune tissues [9–13].
Our reproducible SIV macaque model of HIV/AIDS and CNS
disease provides an opportunity to examine the brain and
periphery during specific time points during acute and early
infection. We previously have characterized innate immune
response in the brain that regulated the transcriptional regulation
of virus in infected macrophages in vitro and in vivo during acute
infection.
Our earlier studies in the SIV macaque model demonstrated
that there is virus replication in the brain during acute infection.
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brain despite reduction in viral replication. SIV DNA levels
remain constant in the brain from acute- to late-stage disease;
however, there is a shift in transcriptionally active to inactive SIV
DNA during the asymptomatic period [12,14,15]. Induction of
innate immune responses in brain macrophages—the predomi-
nant productively-infected cells in the brain—can suppress SIV
gene expression in these cells, resulting in cerebrospinal fluid (CSF)
and brain viral load reductions. We have further demonstrated
that induction of IFNb, the first type I IFN to be produced in
response to viral infections, reduces SIV replication in vitro in
primary macaque macrophages by a transcriptional mechanism.
Additionally, acute infection IFNb induction in the brain
correlates with repression of SIV transcription in macrophages;
this correlation is also observed with the IFNb downstream
transcriptional regulatory pathway protein C/EBPb, a member of
the CCAAT/enhancer binding protein family of transcription
factors in macrophages [14–26]. In addition to controlling virus
infection, IFNb-induced genes—particularly C/EBPb—regulate
inflammatory gene cascades, limiting inflammation and damage in
tissues [26–31].
Understanding the regulation of inflammatory pathways in the
brain during infection and the molecular events linked to control
of inflammation is critical to preventing the development of HIV
encephalitis and cognitive changes observed in HIV-infected
individuals. HIV-1 and SIV infection upregulate the inflammatory
cytokines IL1b, TNFa and IL-6 in brain in macrophages, as well
as the chemokine CCL2 in macrophages and astrocytes [32–39];
this induction, along with the induction of type I IFNs, promotes
antiviral responses. However, these cytokines, including IFNb and
C/EBPb, also prevent inflammatory responses from continuing
unchecked [26–31]. IFNb regulates the transcription factor C/
EBPb, which is critical to the transcriptional regulation of the
proinflammatory genes IL-6, CCL2 and TNFa [29,40,41].
Previous studies in our model demonstrated that increased levels
of C/EBPb in macrophages and the brain led to the decreases in
RNA transcription and SIV promotor histone acetylation [14,15].
The dominant-negative form of C/EBPb also may be important
for regulation of proinflammatory genes in the HIV-1- or SIV-
infected brain.
Using our SIV macaque model of HIV/AIDS and CNS
disease, we demonstrate in this study that infection of the brain
occurs during the earliest phase of acute infection. By 4 days post-
inoculation (p.i.), SIV replication is detected in CD14+ macro-
phages in the brain and infection is accompanied by a widespread
innate immune response. Further, there is coordinated induction
of TNFa, IL10 and CCL2 in the brain during acute infection.
Following acute infection (4–10 days p.i.), there is a decrease in
the levels of proinflammatory cytokines in the brain, accompanied
by a reduction in inflammatory markers in macrophages,
endothelial cells and astrocytes in brain. This downregulation of
cytokines and SIV in the brain is not sustained; increased
expression can occur macaques with development of CNS disease
by 42 days p.i.
Results
In previous studies we examined SIV virus load, CCL2 and IL6
protein in CSF from infected macaques [9,36,37,42–44]. In this
study, we quantified virus replication, proinflammatory cytokines
and innate immune responses directly in the brain of SIV-infected
macaques at multiple times during acute and early stages of
infection to correlate them with longitudinal disease progression.
In addition, SIV-infected macaques were euthanized at 42 days
p.i. to examine cytokine and innate immune responses that are
present during resurgence of virus replication.
SIV Infection and Innate Immune Responses in Brain at 4
Days P.I.
Based on our previous studies, SIV viral load is detectable at 7
days p.i. in the plasma and CSF of infected macaques, while SIV
mRNA in the brain is observed at 7 and 10 day p.i.
[9,36,37,42,43]. In this study, we examined the brain of SIV-
infected macaques at 4 days p.i. to determine when virus infection
in the brain occurs compared to the peripheral blood. There was
significant virus in the peripheral blood (median of 5.2610
6 SIV
RNA copy eq./ml plasma in 6 SIV-infected macaques) and in
CSF (median of 3.5610
4 RNA copy eq./ml CSF) at 4 d p.i. at
these early time points (Figure 1). SIV RNA also was detected in
the brain (basal ganglia and the adjacent white matter and
cerebral cortex) in 6 of 6 SIV-infected macaques at this early time
point (Table 1). Since there is no evidence that there is breakdown
of the blood brain barrier at or that virus is transported across the
blood brain barrier these data strongly suggest that virus enters
and replicates in the brain during the earliest period of acute
infection in the peripheral blood.
To determine whether macrophages in the brain are infected at
4 days p.i., macrophages were isolated from brain of the SIV-
infected macaques euthanized at 4 days p.i. (as previously
described [45]). From the isolated brain macrophages, CD14+
macrophages were selected with CD14-antibody coated beads and
Figure 1. Quantitation of SIV virion RNA in plasma and CSF of
SIV-infected macaques. SIV RNA was isolated from 140 ml of plasma
and CSF collected at terminal time points from uninfected and SIV-
infected macaques sacrificed at 4, 7, 10, 14, 21, or 42 days p.i. SIV RNA
copy equivalents were determined by quantitative RT-PCR, and the
means (diamonds for plasma and squares for CSF) and standard
deviation for each experimental group are indicated.
doi:10.1371/journal.pone.0008129.g001
Table 1. SIV Replication in Brain 4 Days P.I.
SIV RNA Copy equivalents/ug RNA
Brain homogenate 191 (47–399)
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antibody coated beads. The CD14+ macrophages have recently
entered the brain and are located in the perivascular region, while
the CD11b+ (CD142) macrophages represent the resident brain
microglia in the brain parenchyma [46–50]. The CD14+
macrophages had significantly higher levels of SIV RNA than
the brain homogenates from basal ganglia or parietal cortex
(Table 1), while the CD11b+ population had low or no detectable
SIV RNA. These data strongly suggest that the CD14+
macrophages that have recently entered the brain are the source
of SIV replication during the earliest period of CNS infection and
virus is not replicating to a significant level in microglia at this
time.
Viral infection in the brain is accompanied by innate immune
responses, in particular, the induction of mRNA for IFNb and
MxA [14,15,25]. Almost all cells express the IFNa/b receptor,
thus, once the innate immune response is initiated by infection in
the cell, soluble IFNb binds to many cells inducing IFNb and IFN-
induced genes, such as MxA. The levels of IFNb and MxA
mRNAs were measured in brain homogenates and isolated
macrophages from the brain of SIV-infected macaques euthanized
at 4 days p.i. (Table 2). IFNb mRNA was induced 1.8-fold in SIV-
infected brain homogenate over uninfected levels; this induction
was comparable to levels induced in SIV-infected macrophages in
vitro [14,25]. The increase in IFNb mRNA has a multiplicative
effect on the downstream MxA mRNA, which is induced .50 fold
(Table 2), reflecting the induction of the innate immune responses
in the brain at 4 days p.i. In comparison when the CD14+
macrophages were analyzed, there was a 38 fold increase in the
induction of IFNb mRNA and over a 800 fold increase in MxA
RNA, reflecting the response to SIV replication in these cells as
well as the paracrine response to IFNb produced by the infected
CD14+ macrophages. In contrast, the CD11b+ microglia that
contain low levels of SIV RNA had a 200 fold increase in IFNb
mRNA and a 830 fold increase in MxA RNA, reflecting a
paracrine response to the IFNb produced in the infected CD14+
macrophages.
SIV Replication in Peripheral Blood and Brain
To compare virus replication in peripheral blood, CSF, and
brain, SIV RNA isolated from plasma and CSF was measured by
quantitative RT-PCR at the terminal time point for each of the 55
SIV-infected macaques (Figure 1). There was a difference in the
increase in virus during acute infection in plasma (4–7 days p.i.)
compared to CSF (4–7 days p.i. and 4–10 days p.i.) as well as in
the peak of levels of virus, in plasma the peak was at 7 days p.i.
compared to 10 days p.i. in CSF. The difference in levels and peak
of virus in the peripheral blood and CSF could be due to the delay
in virus infected cells entering the brain as well as the different cells
in the two compartments that support virus replication, predom-
inantly, CD4+ lymphocytes in the peripheral blood compared to
macrophages in the brain.
In both plasma and CSF, viral load decreased approximately
10-fold from the peak level at 14 days p.i. Decrease in the levels
of virus occurred more rapidly in CSF (from 10–14 days p.i.) than
in plasma (from 7–14 days p.i. and from 10–14 days p.i). The
decrease in SIV replication in brain has been shown in our model
to be due to the effects of IFNb produced in response to infection
that reduces SIV transcription in macrophages [9,14] but does
not have this effect in CD4+ lymphocytes. Further, the more
rapid decline in SIV in CSF suggests that there are different
mechanisms that control SIV replication in plasma versus CSF or
brain.
Median brain SIV RNA levels for six macaques showed a rapid
increase between 4 and 10 days p.i., with very little change
between 10 and 14 days p.i. (Figure 2). SIV RNA levels were
more variable at 21 days p.i. The rapid increase in SIV RNA
from 4–10 days p.i., followed by the small increase between 10
and14 days p.i., indicates control of SIV replication, which is
reflected in the CSF as a 10-fold reduction in virus. At 42 days
p.i., SIV RNA levels showed a wide range of virus replication:
from levels below day 4–21 days p.i. to levels 100–1000–fold
higher than 21 days p.i. Thus, in some of the SIV-infected
macaques virus replication appears to have been controlled,
while in others virus replication resurged to levels much higher
than during acute and early infection. However, there was no
difference in the level of virus in the plasma of the macaques that
controlled SIV replication in the brain compared to those that did
not. The level of SIV RNA in brain correlated with the severity of
CNS lesions (r=0.95; p,0 . 0 0 1 )( T a b l e3 )w h i l et h e r ew a sn o
correlation between the level of virus load in the plasma and the
severity of CNS lesions.
Table 2. Innate Immune Response in Brain 4 Days P.I.
IFNb mRNA* MxA mRNA*
Brain homogenate 1.8 54.1




*Fold increase compared to uninfected control levels in brain.
doi:10.1371/journal.pone.0008129.t002
Figure 2. SIV RNA expression in brain of SIV-infected
macaques. SIV RNA copies were quantitated by quantitative RT-PCR
in RNA isolated from brain collected at each terminal time point from
uninfected and SIV-infected macaques (4, 7, 10, 14, 21, or 42 days after
inoculation). Medians (black bars) and the range (vertical bars) for each
experimental group are indicated. The 21 day group (12 macaques)
were split into two groups that had viral RNA levels above or below the
median of the 14 day macaques; the median for these two groups are
shown. For the 42 day group, each diamond represents one animal,
color-coded according to CNS disease severity (red - severe; blue -
moderate; turquoise - mild; green–none), and the black bars represent
the medians for severe/moderate (red dotted line), and mild/none
animals (green dotted line).
doi:10.1371/journal.pone.0008129.g002
SIV Infection in Brain
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8129Innate Immune Responses in SIV-Infected Brain
In these studies, IFNb and MxA mRNA levels (as well as all of
the cytokine RNA levels) were quantified by the DDCT method,
normalized to levels in uninfected control macaques, and reported
as fold-change in RNA copies (Figure 3). IFNb mRNA was
induced 1.6- and 2.0-fold over levels in uninfected animals at 4
and 7 days p.i. respectively, and was reduced to comparable with
uninfected animals at 10 and 14 days p.i. The IFNb-induced gene
MxA was induced 54- and 63-fold over uninfected levels at 4 and 7
days, respectively, in parallel with IFNb induction; and at 10 and
14 days induction was reduced to 11- and 2.7-fold, respectively.
IFNb and MxA mRNA levels were elevated over uninfected
control levels in the brain of 3/11 macaques euthanized at 21 days
p.i. At 42 days p.i., IFNb levels in the brains of 6/9 SIV-infected
macaques were lower than in uninfected animals and in the
remaining animals they were induced 3–4 fold over uninfected
levels. There was no correlation with SIV RNA levels; however,
MxA in the brain of SIV-infected macaques sacrificed at 42 days
p.i also varied widely, but levels were correlated with SIV RNA
levels in the macaques with severe and moderate CNS lesions
(r=0.90, p,0.001) (Table 3).
IFNb RNA is regulated by sequences in the 39 UTR that
mediate rapid turnover of the RNA [51]. To assess whether IFNb
protein levels in brain correlated directly with SIV RNA levels,
IFNb protein in brain was measured by quantitative Western
analyses (Figure 4). IFNb protein levels increased 1.5- and 4.0-fold
compared to uninfected levels at 4 and 7 p.i.; there were also
increased levels of protein compared to uninfected controls at 10
and 14 days p.i. Both IFNb protein and mRNA levels decreased at
21 days p.i. At 42 days p.i. there was no correlation between SIV
RNA levels and either IFNb mRNA or protein expression
(Figure 4 and Table 3).
TNFa response occurs concomitant with type I IFN responses
and is one of the first responses to viral infection of macrophages.
TFNa is induced, like IFNb, through the intracellular RNA
helicase, RIG-I [52–55]. TNFa mRNA in the brain was increased
at 4 days p.i. (Figure 3), reached the highest level at 10 days p.i., and
then decreased to pre-infection levels by 14 days p.i. This pattern of
change during acute SIV infection in the brain paralleled that
observed for IFNb mRNA. At 42 days p.i., TNFa mRNA levels fell
into two groups: 3/9 macaques had levels of induction greater than
20-fold, while 6/9 had levels of induction 6-fold or lower
(Figure 3C). Unlike IFNb mRNA levels at 42 days p.i, TNFa
mRNA correlated with SIV RNA levels (r=0.86, p=0.003).
Figure 3. Quantitation of mRNA in brain of SIV-infected
macaques. A) IFNb; B) MxA; and C) TNFa mRNA was isolated from
brain of uninfected and SIV-infected macaques at terminal time points
(4, 7, 10, 14, 21, or 42 days after inoculation) and mRNA levels
quantitated by quantitative RT-PCR. mRNA levels in the SIV-infected
brain are represented as fold change over the average of three
uninfected brain RNAs, calculated by DDCt. Medians (black bars) for
each experimental group are indicated. For the 42-day group, each
diamond represents one animal, color-coded according to CNS disease
severity (red-severe; blue-moderate; turquoise-mild; green-none), and
the black bars represent the medians for severe/moderate (red dotted
line), and mild/none animals (green dotted line). Outliers whose values
were higher than 5 times the standard deviation for each group were
excluded.
doi:10.1371/journal.pone.0008129.g003
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42 Days P.I.
We previously demonstrated that there is induction of C/EBPb-
3—the dominant-negative isoform of C/EBPb—in the brain of
SIV-infected macaques at 7, 10 and 21 days p.i., and that the level
of C/EBPb-3 correlates with the suppression of SIV RNA [14,15].
Here we examined the levels of C/EBPb-2 and C/EBPb-3 in the
brain of the SIV-infected macaques euthanized at 42 days p.i. to
determine whether there was a correlation between the ratio of
C/EBPb-3:C/EBPb-2 and the level of expression of viral RNA.
Since there are no antibodies that distinguish the C/EBPb-2
and C/EBPb-3 isoforms, quantitative Western blot analyses were
performed on brain homogenates from macaques euthanized at 42
days p.i. and the ratio of C/EBPb-3:C/EBPb-2 was measured
(Table 4). There was an inverse correlation (r=20.78, p=0.02)
between the ratio of C/EBPb-3:C/EBPb-2 and the level of SIV
RNA in the brain. There was also an inverse correlation with IL6
mRNA levels (r=20.67, p=0.05). We observed previously that
higher ratios of C/EBPb-3:C/EBPb-2 correlated with reduction
of SIV replication during acute infection and these results supports
a strong role for the induction of C/EBPb-3 by IFNb and
potentially other IFNb pathways that control SIV replication and
cytokines.
Cytokines mRNA Levels in the Brain
CCL2 and IL6 have been correlated with the development of
CNS disease in HIV. In addition to CCL2 and IL6 mRNA
quantification, we measured mRNA of IL10 and IL12, whose
secretion defines differently activated subsets of macrophages
(Figure 5) [56]. CCL2 mRNA increased at 4 days p.i., peaked at 7
days p.i. and decreased at 10 and 14 days p.i. At 21 days p.i.
CCL2 levels increased in parallel with SIV RNA (Figure 5A).
Similarly, IL6 mRNA was induced, consistent with observations in
CSF that IL6 changes paralleled those of CCL2. IL6 mRNA levels
peaked at 7 days p.i., were at the lowest level of induction at 14
days p.i., and increased at 21 and 42 days p.i. (Figure 5B). IL10
mRNA peaked during acute infection at 4 days p.i. and then
declined to uninfected levels by 7–14 days p.i. (Figure 5C). IL10
mRNA levels were elevated again at 21 days p.i. and by 42 days
p.i. In contrast to the other cytokines examined, IL12 (p40) mRNA
levels were lower than levels in uninfected animals throughout
acute infection, never increasing to levels above those in
uninfected macaques (Figure 5D). The acute infection levels of
IL12 mRNA showed an inverse pattern compared to IL10 mRNA
levels. Thus, all the mRNAs examined, except for IL-12, increased
during acute infection and then declined to uninfected levels in the
brains of the macaques euthanized at 14 days p.i. This appears to
represent a coordinated downregulation of the initial inflamma-
tory cytokine responses that are triggered at 4 days p.i. by virus
infection in macrophages in brain.
Expression of Macrophage, Endothelial Cell and
Astrocyte Inflammatory Proteins during Acute Infection
and Early Disease
To examine the expression of proteins associated with cellular
activation or inflammatory responses during acute infection in
brain macrophages, astrocytes and endothelial cells, sections of
brain (basal ganglia) were stained for CD68 (macrophage
activation marker), MHC Class II (macrophage and endothelial
cell activation marker), and GFAP (astrocyte activation marker).
At 4 days p.i., MHC Class II and CD68 expression increased
in the SIV-infected brain by 2.4- and 7-fold, respectively
(Figures 6A and 6B). Expression rapidly returned to uninfected
levels at 7 and 10 days p.i. While CD68 is found exclusively in
macrophages, MHC Class II is exp r e s s e di nb o t hm a c r o p h a g e s
and endothelial cells. At 4 days p.i., MHC Class II was almost
exclusively expressed in endothelial cells in the SIV-infected
brain (Figure 6), whereas at later time points, it was expressed in
endothelial cells but more prominently in macrophages. GFAP
expression in astrocytes also increased 1.7-fold at 4 days p.i.
(Figure 6C). The expression of all three of these cellular
activation proteins decreased by 10 days p.i. and increased
expression occurred between 14 and 21 days p.i. At these time
points, MHC Class II expression was detected in both
macrophages and endothelial cells. At 42 days p.i., the expression
level of all three cellular activation proteins correlated with the
severity of CNS disease in the brain and with levels of SIV RNA
in brain (MHC CLASS II and CD68 r=0.95, p,0.001; GFAP
r=0.74, p=0.03) (Table 4).
Figure 4. IFNb protein levels in brain of SIV-infected macaques.
Brain homogenates were made from brain from uninfected and SIV-
infected macaques at terminal time points (4, 7, 10, 14, 21, or 42 days
after inoculation) and IFNb protein was quantitated by quantitative
western analyses as described in Methods and Materials. Medians (black
bars) for each experimental group are indicated. For the 42 day group,
each diamond represents one animal, color-coded according to CNS
disease severity (red-severe; blue-moderate; turquoise-mild; green-
none), and the black bars represent the medians for severe/moderate
(red dotted line), and mild/none animals (green dotted line). Protein
band intensities were normalized to GAPDH.
doi:10.1371/journal.pone.0008129.g004
Table 4. SIV RNA and Ratio of C/EBPb-3/C/EBPb-2 in SIV-
infected Macaque Brain at 42 Days P.I.
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SIV encephalitis is characterized by numerous perivascular cuffs
of epithelioid macrophages and multinucleated giant cells, as well
as multifocal nests of activated macrophages and astrocytes in the
parenchyma. These lesions are very similar to HIV encephalitis,
except that SIV-infected macaque brains often contains more
lymphocytes; this is probably due to the fact that macaques are
euthanized when they exhibit any clinical signs of disease, so the
CNS is likely examined at an earlier stage of CNS disease
progression [57].
Approximately 55% (5/9) of macaques euthanized at 42 days
p.i. developed neurological disease: 2 macaques were classified
pathologically with mild CNS lesions, 1 with moderate CNS
lesions, and 2 with severe CNS lesions. In our previous studies in
the SIV macaque model, we found that 90% (26/29) of macaques
euthanized at 84 days p.i., developed neurological disease and
41% were classified as severe CNS lesions [58]. For macaques
euthanized at 42 days p.i., there was a significant correlation
between SIV RNA levels and the severity of CNS disease (r=0.95;
p,0.001). The strong correlation between viral RNA levels in the
brain and the severity of CNS lesions has been reported previously
in this model in SIV-infected macaques euthanized at 84 days p.i.,
but had not been observed as early as 42 days p.i. [43,58]. At 42
days p.i., IL6 and IL10 mRNA levels correlated with CNS lesion
severity (r=0.71, p=0.04 and r=0.69, p=0.05, respectively).
Discussion
While HIV and SIV infect the brain during acute infection,
there is no evidence of cognitive alterations or ongoing
inflammatory changes in the brain during this early CNS
infection. Other studies have demonstrated SIV infection in the
brain during early infection, as well as the induction of innate
immune responses; however, there are no HIV or SIV studies that
have examined all of these viral and cellular changes in the same
macaques on a longitudinal basis throughout acute infection
[33,59]. This is due, in part, to the variable course of disease in
Figure 5. CCL2, IL6, IL10, and IL12 mRNA in brain of SIV-infected macaques. mRNA was isolated form brain of uninfected and SIV-infected
macaques at terminal time points (4, 7, 10, 14, 21, or 42 days after inoculation). mRNA levels for A) CCL2; B) IL6; C) IL10; and D) IL12 was measured by
quantitative RT-PCR and mRNA levels in the SIV-infected are represented as fold change over the average of the uninfected values, calculated by
DDCt. Medians (black bars) for each experimental group are indicated. For the 42-day group, each diamond represents one animal, color-coded
according to CNS disease severity (red-severe; blue-moderate; turquoise-mild; green-none). The black bars represent the medians for severe/
moderate (red dotted line), and mild/none animals (green dotted line).
doi:10.1371/journal.pone.0008129.g005
SIV Infection in Brain
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infected macaques that take years to develop AIDS with only a
subset of humans or macaques developing CNS disease. In this
study we have used our consistent and accelerated SIV model, in
which all infected macaques develop AIDS and 90% develop
mild-severe CNS disease by 3 months p.i.; the consistent CNS
disease development makes this model ideal for the study of CNS
lesion development and associated events in the brain. In this
study a total of 55 SIV-infected macaques were euthanized at 4, 7,
10, 14, 21 and 42 days p.i. to examine the viral and cellular
changes that occur from acute infection at 4–10 days p.i. to the
early development of disease between 21 and 42 days p.i.
These studies demonstrate for the first time that a transient but
effective innate immune response in brain effects coordinated
control of both virus replication and the pro-inflammatory
cytokines produced in response to acute infection. We demonstrate
that SIV replication occurs in the brain as early as 4 days p.i.,
predominantly in perivascular macrophages. Virus infection in the
brain at 4 days p.i. was accompanied by IFNb and TNFa
responses; these antiviral responses waned rapidly by 14 days and
there was control of virus replication during this period. IFNb and
MxA mRNAs were upregulated in both the CD14+ and CD11b+
macrophage populations from the brain, while virus replication
was predominantly in the CD14+ macrophages, suggesting that
innate immune responses are more widespread than the SIV
infection in these cells. Thus, both SIV infection and the
accompanying innate immune response in brain and in macro-
phages enriched from brain are detectable as early as 4 days p.i.—
at the same time that virus replication is detected in the peripheral
blood.
In addition, the induction of the cytokines IL6, IL10, and the
chemokine CCL2 occurred during acute infection (Figure 7).
CCL2 is produced in astrocytes in response to HIV and SIV
infection of the CNS [35,60,61]. CCL2 secretion in the brain is
thought to create a gradient that recruits peripheral blood
monocytes and activated and infected lymphocytes into the brain
[62,63]. In addition, production of CCL2 by astrocytes has been
demonstrated in vitro to have neuroprotective effects in astrocytes
and neurons by inhibiting apoptosis [64].
We also observed induction of the dominant-negative isoform of
C/EBPb, C/EBPb-3, which is a key mediator in this cytokine
cascade. The C/CAAT family protein C/EBPb is important in
regulating the expression of cytokines and has been implicated in
anti-inflammatory control by IFNb [26,29,30,40,65,66]. There are
multiple protein isoforms of C/EBPb and these differ in structure
and function. The major isoform translated from the second AUG
in the C/EBPb mRNA (referred to LAP in rodents and C/EBPb-
2 in humans) contains the transcriptional activation domain as well
as the DNA binding domain and activates transcription. The
isoform that is translated from the third AUG in the C/EBPb
Figure 6. Expression of MHC Class II, CD68 and GFAP in brain of SIV-infected macaques. Quantitative immunohistochemistry was used to
measure A) MHC class II; B) CD68; and C) GFAP in brain from SIV-infected macaques at terminal time points (4, 7, 10, 14, 21, or 42 days p.i.). The
quantification of each protein is based on the mean of 20 measures on brain from each macaque. D) MHC class II expression in brain at 4 days p.i. E)
CD68 expression in brain at 4 days p.i.
doi:10.1371/journal.pone.0008129.g006
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only the DNA binding domain and functions in the presence of
LAP or C/EBPb-2 as a dominant-negative transcriptional
repressor [16,67]. The ratio of the two isoforms is important in
regulating transcription of a number of cytokine genes, including
CCL2, IL-6, IL-10 and TNF-a. The C/EBPb-3:C/EBPb-2 ratio
also regulates SIV transcription in vitro in primary macrophages as
well as SIV replication in brain (in which macrophages/microglia
are the primary productively infected cells) [14,25]. In this
previous study, the level of C/EBPb-3 in brain of SIV-infected
macaques increased from 7–21 days and this correlated with the
reduction of SIV mRNA in brain, as well as the level of acetylation
of histone H4 downstream from the SIV transcriptional start site.
Unlike C/EBPb-2, C/EBPb-3 does not recruit histone acetylases
to the promoter and the promoter is deacetylated when C/EBPb-3
is present in the promoter and transcription is suppressed
[14,15,25].
Both IL-10 and IFNb have been demonstrated to induce the
expression of C/EBPb-3, contributing to the induction of this
isoform of C/EBPb in the brain during acute infection [23]. IFNb
and IL10 induction of C/EBPb-3 plays an important role in the
anti-inflammatory control for these two cytokines in macrophages
and it appears that the level of C/EBPb-3 correlate with
expression of virus during acute infection, as well as the level of
virus replication at 42 days p.i. Thus, in this study we have
demonstrated that a cellular transcription factor that is induced by
IFNb and IL-10 is important in the brain for regulating virus
replication and the expression of pro-inflammatory cytokines that
are strongly linked to CNS inflammation and HIV-associated
CNS disease. We have now demonstrated that C/EBPb-3 levels
correlate with not only virus replication in the brain, but the
severity of CNS lesions and expression of inflammatory proteins in
macrophages, endothelial cells and astrocytes, suggesting that this
is an important pathway for controlling the progression of HIV
and SIV CNS damage and disease processes.
An exception to the observed general pattern of cytokine
induction was expression of the pro-inflammatory cytokine IL12,
which was markedly suppressed during all stages of infection. A
recent cohort study demonstrated that IL12 expression was
deficient in chronically infected HIV individuals, although IL12
was induced in the periphery during acute infection [68]. It is clear
from our studies that the inflammatory IL12 response during acute
phase is different between the periphery and the CNS, with
repression of IL12 observed in brain at all time points in our
model. The function of IL12 in peripheral infection is thought to
include stimulation of CD4+ help in the CTL process. [69] This
role is unlikely to be as important in the brain during acute
infection, which is marked by low numbers of brain lymphocytes
and low proportions of CTLs and NKs [70].
The transient expression of CD68 in macrophages, MHC Class
II in endothelial cells and GFAP in astrocytes at 4 days p.i.
demonstrates that cellular pro-inflammatory responses are trig-
gered during acute infection and, like the cytokine and chemokine
responses, rapidly return at 7–10 days p.i. to levels observed in
uninfected macaques. This provides evidence at the cellular level
that the coordinated regulation of pro-inflammatory genes occurs
in endothelial cells, perivascular macrophages and astrocytes. The
decreased expression of MHC Class II expression on endothelial
cells would be expected to decrease the entry of monocytes and
lymphocytes into the CNS and contribute to the control in virus
replication observed.
Our studies further indicate the development of two patterns of
viral replication in brain as early as 21 days p.i.: one characterized
by SIV RNA levels lower than day 10 and 14 p.i. levels and one
characterized by higher levels. Indeed at 42 days p.i. the two levels
of virus replication strongly correlate with the severity of CNS
lesions, as well as CD68, MHC CLASS II and GFAP protein
levels in brain. We also observed a correlation between IL6 and
IL10 levels and CNS lesion development at 42 days p.i..
The coordinated control of virus replication and inflammation
suggests that there are specific—and possibly common—mecha-
nisms in the brain that limit inflammatory processes produced in
response to HIV and SIV infection and provides an explanation
for the lack of neurological deficits and CNS inflammation during
acute HIV infection in the brain. Our data suggest that the level of
C/EBPb-3 in brain plays an important role in regulation, although
there are likely additional pathways that are involved in regulating
the inflammatory responses. If the regulatory mechanisms that
impact both virus replication and pro-inflammatory cascades fail
to control virus replication, virus then induces both IFNb and
TNFa; however, at this stage of the infection (by 21 days p.i.)
adaptive immune responses have been induced and the presence
of the adaptive along with the innate immune responses probably
contribute to the inability of the anti-inflammatory mechanisms to
regulate either virus replication or infection-induced inflammatory
responses.
We have previously demonstrated that treatment with minocy-
cline, an antibiotic that has anti-inflammatory effects in the brain,
can impact the inflammatory response to SIV at 21 days p.i. when
initiated after acute infection [71]. The data reported here,
together with the minocycline studies, suggest that therapeutic
intervention with specific drugs that control HIV infection and/or
the inflammatory responses in the brain could prevent the
cognitive changes and encephalitis that continue to affect HIV-
infected individuals in the HAART era. Further, these studies
indicate that increases in either virus or CCL2 in the CSF clearly
mirror events in the brain and should be monitored in HIV
infected individuals and used to initiate either CNS-penetrating
antiretrovirals or anti-inflammatory therapy capable of crossing
the blood brain barrier.
T h e s es t u d i e sd e m o n s t r a t et h a tt h e r ea r em e c h a n i s m si nb r a i n
that induce coordinated control of both virus replication and the
inflammatory cytokines produced in response to infection. The
results suggest that the inflammatory responses required to limit
virus replication in the brain must also be tightly controlled so as
Figure 7. Coordinated expression of innate immune genes and
cytokines in brain of SIV-infected macaques during acute
infection in brain. A schematic of median values of mRNA levels for
all cytokines measured by RT-PCR in brain tissue from uninfected and
SIV-infected macaques euthanized at different time points (4, 7, 10, 14
and 21 days p.i.).
doi:10.1371/journal.pone.0008129.g007
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trigger neuronal damage and cognitive impairment. A loss of
this inflammation-limiting capacity may contribute to the
progression to encephalitis in late stage disease. The studies
reported here provide the first step in identifying these pathways
a n do u rm o d e lw i l lb eu s e dt oi dentify additional cellular
signaling pathways that regulate infection and inflammatory
changes in the brain.
Methods and Materials
Viruses and Animal Studies
Forty-four juvenile pigtailed macaques (Macaca nemestrina)
were intravenously inoculated as previously described with SIV/
DeltaB670 (50 AID50) and SIV/17E-Fr (10,000 AID50)[ 4 3 ] .
CSF and plasma samples were taken on days 7, 10, 14, 21, 28,
35, 43, 56, 70, 77 and 84 for quantitation of viral RNA, and
ELISA quantitation of monocyte chemoattractant protein
(CCL2) and IL6 [36,37,43]. Macaques were euthanized at 4
(6 macaques), 7 (11 macaques), 10 (12 macaques), 14 (6
macaques), 21 (12 macaques) and 42 (9 macaques) days p.i. in
accordance with federal guidelines and institutional policies. At
euthanasia, macaques were perfused with sterile saline to
remove blood from the vasculature prior to freezing or fixing
tissues.
All animal studies were approved by the Johns Hopkins
University Institutional Animal Care and Use Committee and in
accordance with the recommendations of the Weatherall Report.
Early endpoints are adopted for this study including aggressive
monitoring of bloodwork parameters and humane euthanasia
once progressive disease is noted. All animal housing and care is
conducted according to the Guide for the Care and Use of
Laboratory Animals and the United States Department of
Agriculture Animal Welfare Act. All non-human primates receive
environmental enrichment including manipulanda, foraging, and
opportunity to exhibit species-specific behavior. Animals are pair
or group housed when possible.
Quantitation of SIV Virions in Plasma and CSF
Virus was quantitated in plasma and CSF from 140 mlo f
plasma and CSF collected longitudinally as well as at the terminal
time point. Viral RNA was isolated directly from plasma and
CSF using the QIAamp Viral RNA Mini kit (Qiagen), according
to the manufacturer’s protocol. Quantification of virion-associat-
ed RNA was performed by real-time RT-PCR as previously
described [15].
Quantitation of Viral and Cellular Genes in Brain Tissue
Total RNA was isolated from 50 mg of brain tissue (basal
ganglia and parietal cortex) by use of the RNeasy kit (Qiagen), and
treated with two units of Turbo DNase (Ambion) for 30 minutes at
37uC. One microgram of purified RNA was analyzed by real-time
RT-PCR using specific primers and probes for SIV gag [15] and
each of the studied cytokines (Table S1). PCR reactions were
performed in a Chromo4 thermocycler (Biorad) using a Multiplex
PCR Mix (Qiagen). Cellular mRNA levels were normalized by
18S ribosomal RNA levels. Quantitation of gene expression was
performed using the DD Ct method [72].
Quantitation of IFN-ß and C/EBP-ß Proteins
Western blot analysis was performed on lysed punches of brain
tissue (snap-frozen). Briefly, 50 mg of brain tissue was homoge-
nized in RIPA buffer containing protease inhibitors (Sigma).
Proteins (40–80 mg) were separated on 4–12% SDS-polyacryl-
amide gels and transferred onto polyvinylidene difluoride
membranes (PVFD) membranes. Blots were blocked with 0.5%
fetal bovine serum and probed for the respective proteins with
specific primary antibodies, using a Snap ID apparatus (Millipore).
C/EBPb (C-19) and GAPDH antibodies were purchased from
Santa Cruz. Human IFNb antibody was purchased from PBL
InterferonSource (Piscataway, NJ). After incubation with fluores-
cence-conjugated secondary antibodies (GE Healthcare; Invitro-
gen), the membranes were visualized on a Typhoon 9400 scanner
(GE Healthcare). Band intensities were measured and analyzed
using ImageQuant software (GE Healthcare). For the IFNb
western blots, equal protein loading was confirmed by comparison
with the intensity of GAPDH.
Isolation of CD14+ and CD142/CD11b+ Brain Cells
Microglial cells from the subcortical white matter from six
macaques sacrificed at 4 days p.i. were isolated as previously
described [45]. CD14+ cells were selected with specific magnetic
Dynabeads (Invitrogen) according to the manufacturer’s protocol.
After three washes with wash buffer (2% BSA in PBS), the
unselected portion was promptly incubated with CD11b+
Dynabeads (Invitrogen). Both CD14+ and CD142/CD11b+ cell
populations were snap-frozen for future RNA isolation.
Quantitative Immunohistochemical Analysis
Our methods for quantitative immunohistochemical analysis of
CD68, MHC CLASS II and GFAP have been described
previously [15,36,43,70].
Pathological Assessment
All tissues were examined microscopically by two pathologists
(CZ, JM). Sections of frontal and parietal cortex, basal ganglia,
thalamus, midbrain, cerebellum and brain stem were examined
microscopically and scored independently as mild, moderate, or
severe and were each given numerical scores of 1 (mild), 2
(moderate), or 3 (severe) by using a semiquantitative system as
described [43].
Statistical Analysis
A non-parametric method of comparison (Wilcoxon rank-sum
test) was used for comparisons between SIV encephalitis severity
groups of macaques (i.e., none and mild versus moderate and
severe groups). T-tests were not performed since many variables
required mathematical transformations (e.g. Log 10) to meet
normality requirements. Expression of MHC II, CD68, GFAP
and gp41 in the brain were quantitated using 20 separate
measures on each tissue sample; the mean was used for analyses.
Spearman’s rank correlation test was used to determine the
degree of correlation between each measure. Spearman’s is an
analogous non-parametric to be used in place of Pearson’s
estimate if either variable under consideration is found to be
highly skewed. Non-parametric methods are considered to be
conservative; therefore statistically significant results found
when using non-parametric methods are assumed to imply a
lower bound for the p-value. All statistical tests were performed
as two-sided tests.
Supporting Information
Table S1 Primers and probes for SIV gag and cytokines.
Primers and probes used for real-time RT-PCR analysis of SIV
gag and each of the studied cytokines.
Found at: doi:10.1371/journal.pone.0008129.s001 (0.39 MB TIF)
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